Quest Diagnostics (DGX) risk factors, FY2025 10-K

RISKS RELATED TO OUR BUSINESS

1. 01The U.S. healthcare system continues to evolve, and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt
2. 02The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability
3. 03Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services42% rewritten
4. 04Reimbursement for Medicare services also is subject to annual reduction under the Budget Control Act of 2011, and the Statutory Pay-As-You-Go Act of 201053% rewritten
5. 05Health plans and other third parties have taken steps to reduce the utilization and reimbursement of health services, including clinical testing services31% rewritten
6. 06Failure to develop, acquire licenses for, introduce, or commercialize new tests, technology and services could negatively impact our testing volume, revenues and profitability
7. 07Failure to establish, and perform to, appropriate quality standards, or to assure that the appropriate standard of quality is observed in the performance of our diagnostic information services, could adversely affect the results of our operations and adversely impact our reputation

RISKS RELATED TO CHANGE IN PUBLIC POLICY

1. 08We are subject to numerous legal and regulatory requirements governing our activities, and we may face substantial fines and penalties, and our business activities may be impacted, if we fail to comply
2. 09Our business and operations could be adversely impacted by the FDA's approach to regulation83% rewritten
3. 10Failure to accurately bill for our services, or to comply with applicable laws relating to billing government healthcare programs, could have a material adverse effect on our business
4. 11We are subject to numerous political (including geopolitical), legal, operational and other risks as a result of our international operations which could impact our business in many ways46% rewritten
5. 12We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business
6. 13Adverse results in material litigation could have an adverse financial impact and an adverse impact on our client base and reputation

RISKS RELATED TO OUR INDEBTEDNESS

1. 14Our outstanding debt may impair our financial and operating flexibility

RISKS RELATED TO OUR OPERATIONS

1. 15We have been and expect to continue to use AI technology in the testing services we offer. The challenges with properly managing the development and use of these technological innovations could result in harm to our reputation, business or customers, and adversely affect our results of operations
2. 16Our business could be negatively affected if we are unable to continue to strengthen our efficiency36% rewritten
3. 17Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies31% rewritten
4. 18Our approach to corporate responsibility may not satisfy all our stakeholders21% rewritten
5. 19The IT systems that we rely on may be subject to unauthorized tampering, cyberattack or other security breach
6. 20Our ability to attract and retain qualified employees and maintain good relations with our employees is critical to the success of our business and the failure to do so may materially adversely affect our performance30% rewritten
7. 21Business development activities are inherently risky and integrating our operations with businesses we acquire may be difficult40% rewritten
8. 22Our operations may be adversely impacted by the effects of natural disasters such as hurricanes and earthquakes, public health emergencies and pandemics, geopolitical conflicts, hostilities or acts of terrorism and other criminal activities
9. 23Any future public health emergencies or pandemics may negatively affect us, including through its impact on the labor force and supply chain
10. 24Inflationary pressures could adversely impact us because of increases in the costs of materials, supplies and services, and increased labor and people-related expenses
11. 25CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
12. 26(d) Impact of changes in payment mix, including increased patient financial responsibility and any shift from fee-for-service to discounted, risk-sharing, capitated or bundled fee arrangements36% rewritten
13. 27(i) Denial, suspension or revocation of CLIA certification or other licenses for any of our clinical laboratories under the CLIA standards, revocation or suspension of the right to bill the Medicare and Medicaid programs or other adverse regulatory actions by federal, state and local agencies
14. 28(n) Failure of the Company to maintain, defend and secure its financial, accounting, technology, customer data and other operational systems from cyberattacks, IT system outages, telecommunications failures, malicious human acts and failure of the systems of third parties upon which the Company relies
15. 29(p) Challenges, including the associated competitive pressures, with properly managing the development, implementation, oversight and use of AI
16. 30(2) inability to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully enforce our proprietary rights
17. 31(t) The complexity of billing and revenue recognition for clinical laboratory testing
18. 32(v) Inability to hire or retain qualified employees, including key senior management personnel, and maintain good relations with our employees30% rewritten
19. 33(x) Difficulties and uncertainties in the discovery, development, regulatory environment and/or marketing of new services or solutions or new uses of existing tests22% rewritten
20. 34(cc) Failure to adequately operationalize appropriate controls around use of our data, including risk of non-compliance with privacy law requirementsNew